Four Abstracts By Biopure and Collaborating Scientists Accepted for Annual Meeting of American Society for Clinical Pharmacology and Therapeutics
Posted on: Tuesday, 4 December 2007, 12:00 CST
CAMBRIDGE, Mass., Dec. 4 /PRNewswire-FirstCall/ -- Biopure Corporation announces the acceptance of four abstracts for presentation at the American Society for Clinical Pharmacology and Therapeutics annual meeting to be held April 2-5, 2008. The Society is the largest scientific and professional organization serving the discipline of clinical pharmacology.
These abstracts address the basis for adverse event outcomes and other key findings in previous surgical studies of Hemopure. Biopure and the collaborating scientists also address the safety and efficacy of both Hemopure and Hemoglobin-based oxygen carriers (HBOCs) in general. The titles, authors and affiliations are as follows:
RISK OF ADVERSE OUTCOME DUE TO ACUTE ANEMIA IN THE ORTHOPEDIC SURGICAL SETTING. L. B. Pearce, A. N. Pitman; Biopure Corporation, Cambridge, MA.
BREAKING THE RULES: MISINTERPRETATION OF DOSE-RESPONSE RELATIONSHIPS IN CLINICAL TRIALS. L. B. Pearce, A. N. Pitman, A. G. Greenburg; Biopure Corporation, Cambridge, MA.
A FLEXIBLE OUTCOME SCORING SYSTEM FOR CLINICAL TRIALS. A. N. Pitman, L. B. Pearce; Biopure Corporation, Cambridge, MA.
APPLICATION OF A UNIQUE SCORING SYSTEM FOR NUMERICAL DETERMINATION OF A BENEFIT RISK RATIO IN CLINICAL TRIALS. L. B. Pearce(1), A. Pitman,(1) A. G. Greenburg,(1) D. A. Freilich,(2) L. Kaplan(3); (1)Biopure Corporation, Cambridge, MA, (2)Naval Medical Research Center, Silver Spring, MD, (3)Yale University School of Medicine, New Haven, CT.
Biopure Corporation
Biopure Corporation develops, manufactures and markets pharmaceuticals, called oxygen therapeutics, that are intravenously administered to deliver oxygen to the body's tissues. Hemopure(R) [hemoglobin glutamer - 250 (bovine)], or HBOC-201, is approved for sale in South Africa for the treatment of surgical patients who are acutely anemic. Biopure has applied in the United Kingdom for regulatory approval of a proposed orthopedic surgical anemia indication. The company is developing Hemopure for several other indications and is supporting the U.S. Navy's government-funded efforts to develop a potential out-of-hospital trauma indication. Biopure's veterinary product Oxyglobin(R) [hemoglobin glutamer - 200 bovine)], or HBOC-301, the only oxygen therapeutic approved by both the U.S. Food and Drug Administration and the European Commission, is indicated for the treatment of anemia in dogs. Biopure has sold approximately 186,000 units of Oxyglobin.
Contact: Tiana Gorham Herb Lanzet (Investors) Biopure Corporation H.L. Lanzet Inc. (617) 234-6826 (212) 888-4570 IR@biopure.com lanzet@aol.com
Biopure Corporation
CONTACT: Tiana Gorham, Biopure Corporation, +1-617-234-6826,IR@biopure.com, or Herb Lanzet (Investors), H.L. Lanzet Inc., +1-212-888-4570,lanzet@aol.com
Web site: http://www.biopure.com/
Company News On-Call: http://www.prnewswire.com/comp/131224.html
Source: PRNewswire-FirstCall
Related Articles
- PDS Biotechnology Corporation Demonstrates Pre-Clinical Safety of its Versamune(TM)-Based HPV Product
- Biopure Corporation Receives Notice of Delisting from Nasdaq
- AmpliMed Corporation to Present Clinical Data From Three Clinical Trials of Amplimexon(R) at American Society of Clinical Oncology Annual Meeting
- Health Discovery Corporation Announces Successful Clinical Trial Results for New Molecular Diagnostic Test for Prostate Cancer
- Sarah White, RNP, Tapped As New INSPIRIS Corporate VP for Clinical Operations
- NanoBio(R) Corporation Initiates Phase 2 Clinical Trial for Treatment of Onychomycosis
- Biopure's Phase II Trauma Trial of Hemopure(R) in South Africa Continues Following Independent Panel's First Scheduled Interim Review
- Extra oxygen combats surgical infections: study
- Cytogen Corporation Provides QUADRAMET(R) Clinical Development and Commercialization Update
- Neoprobe Establishes Corporate IND for Lymphoseek; Neoprobe Assumes Corporate Responsibility for Clinical Evaluation
 |
 |
User Comments (0)
RSS Feeds